QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.067959v1 311/1/324    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cundy, K. C. Articles by Gallop, M. A. Search for Related Content PubMed PubMed Citation Articles by Cundy, K. C. Articles by Gallop, M. A.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

XP13512 [(±)-1-([(-Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane Acetic Acid], A Novel Gabapentin Prodrug: II. Improved Oral Bioavailability, Dose Proportionality, and Colonic Absorption Compared with Gabapentin in Rats and Monkeys

XenoPort, Inc., Santa Clara, California

The absorption of gabapentin (Neurontin) is dose-dependent and variable between patients. Rapid clearance of the drug necessitates dosing three or more times per day to maintain therapeutic levels. These deficiencies appear to result from the low capacity, limited intestinal distribution, and variable expression of the solute transporter responsible for gabapentin absorption. Saturation of this transporter at doses used clinically leads to unpredictable drug exposure and potentially ineffective therapy in some patients. XP13512 [(±)-1-([(-isobutanoyloxyethoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid] is a novel prodrug of gabapentin designed to be absorbed by high-capacity nutrient transporters located throughout the intestine. XP13512 was efficiently absorbed and rapidly converted to gabapentin after oral dosing in rats and monkeys. Exposure to gabapentin was proportional to prodrug dose, whereas exposure to intact XP13512 was low. In rats, >95% of an oral dose of ¹⁴C-XP13512 was excreted in urine in 24 h as gabapentin. In monkeys, oral bioavailability of gabapentin from XP13512 capsules was 84.2% compared with 25.4% after a similar oral Neurontin dose. Compared with intracolonic gabapentin, intracolonic XP13512 gave a 17-fold higher gabapentin exposure in rats and 34-fold higher in monkeys. XP13512 may therefore be incorporated into a sustained release formulation to provide extended gabapentin exposure. XP13512 demonstrated improved gabapentin bioavailability, increased dose proportionality, and enhanced colonic absorption. In clinical use, XP13512 may improve the treatment of neuropathic pain, epilepsy, and numerous other conditions by increasing efficacy, reducing interpatient variability, and decreasing frequency of dosing.

Address correspondence to: Dr. Kenneth C. Cundy, XenoPort, Inc., 3410 Central Expressway, Santa Clara, CA 95051. E-mail: kcundy{at}xenoport.com

This article has been cited by other articles:

				C. A. Kushida, P. M. Becker, A. L. Ellenbogen, D. M. Canafax, R. W. Barrett, and The XP052 Study Group Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS Neurology, February 3, 2009; 72(5): 439 - 446. [Abstract] [Full Text] [PDF]

				K. C. Cundy, S. Sastry, W. Luo, J. Zou, T. L. Moors, and D. M. Canafax Clinical Pharmacokinetics of XP13512, a Novel Transported Prodrug of Gabapentin J. Clin. Pharmacol., December 1, 2008; 48(12): 1378 - 1388. [Abstract] [Full Text] [PDF]

				T. Bordet, B. Buisson, M. Michaud, J.-L. Abitbol, F. Marchand, J. Grist, E. Andriambeloson, M. Malcangio, and R. M. Pruss Specific Antinociceptive Activity of Cholest-4-en-3-one, Oxime (TRO19622) in Experimental Models of Painful Diabetic and Chemotherapy-Induced Neuropathy J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 623 - 632. [Abstract] [Full Text] [PDF]

				C. Hilgendorf, G. Ahlin, A. Seithel, P. Artursson, A.-L. Ungell, and J. Karlsson Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines Drug Metab. Dispos., August 1, 2007; 35(8): 1333 - 1340. [Abstract] [Full Text] [PDF]

				K. C. Cundy, R. Branch, T. Chernov-Rogan, T. Dias, T. Estrada, K. Hold, K. Koller, X. Liu, A. Mann, M. Panuwat, et al. XP13512 [({+/-})-1-([({alpha}-Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane Acetic Acid], A Novel Gabapentin Prodrug: I. Design, Synthesis, Enzymatic Conversion to Gabapentin, and Transport by Intestinal Solute Transporters J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 315 - 323. [Abstract] [Full Text] [PDF]